Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | APAF1 | O14727 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18656955 | 0.86 | MAPT (0.50) | MAPTKMT2AHSD17B10MEN1USP2 | |
| SCHEMBL10159096 | 0.81 | KMT2A (0.66) | MAPTKMT2AHSD17B10MEN1USP2 | |
| SCHEMBL10159099 | 0.80 | MAPT (0.69) | MAPTKMT2AHSD17B10MEN1USP2 | |
| SCHEMBL10158776 | 0.80 | KMT2A (1.00) | MAPTKMT2AHSD17B10MEN1USP2 | |
| SCHEMBL10159335 | 0.77 | MEN1 (0.41) | MAPTKMT2AHSD17B10MEN1USP2 | |
| SCHEMBL7954623 | 0.76 | CASP3 (0.59) | MAPTGAAL3MBTL1SLC6A3DAO | |
| SCHEMBL10159081 | 0.76 | MAPT (0.70) | MAPTKMT2AHSD17B10MEN1USP2 | |
| SCHEMBL3419656 | 0.74 | KMT2A (0.87) | MAPTKMT2AHSD17B10MEN1USP2 | |
| SCHEMBL10159301 | 0.74 | MEN1 (0.41) | MAPTKMT2AHSD17B10MEN1USP2 | |
| SCHEMBL15437771 | 0.73 | PARK7 (0.50) | MAPTGAAHTTSLC6A3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3144299-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Cambria Pharmaceuticals, Inc. (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9499494-B2 | Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-9499494-B2 | Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis | NORTHWESTERN UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2427438-B1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20150203456-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2015-07-23 | — | — | US | disclosed |
| US-20150203456-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS DISTRIBUTING TRUST | 2015-07-23 | — | — | US | disclosed |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NORTHWESTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NORTHWESTERN UNIVERSITY (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010129665-A2 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CAMBRIA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203456-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NUDT1, TYMP, HPRT1 | MAPT 6/4885KMT2A 946/4885HSD17B10 4075/4885 |
| US-20120046309-A1 | PYRIMIDINE-2,4,6-TRIONES FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | NUDT1, TYMP, HPRT1 | MAPT 6/4885KMT2A 946/4885HSD17B10 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.